Jalal Zakaria, Iriart Xavier, Dinet Marie-Lou, Selly Jean-Bernard, Tafer Nadir, Renou Pauline, Sibon Igor, Thambo Jean-Benoît
Department of Paediatric and Adult Congenital Cardiology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Department of Paediatric and Adult Congenital Cardiology, University Hospital of Bordeaux, 33000 Bordeaux, France.
Arch Cardiovasc Dis. 2016 Dec;109(12):659-666. doi: 10.1016/j.acvd.2016.02.012. Epub 2016 Jul 8.
Percutaneous left atrial appendage (LAA) closure has emerged as an alternative therapeutic option for the prevention of embolic stroke in high-risk patients with non-valvular atrial fibrillation. The presence of thrombus in the LAA is currently a contraindication to the procedure.
To describe a modified LAA closure technique that allows a safe procedure in patients with LAA thrombus.
Between May 2013 and October 2014, LAA closure was performed in three patients with LAA thrombus (mean age 73.6±14 years; two men), using a modified technique that avoids manipulation of catheters or angiography in the LAA.
Two patients had persistent thrombus despite appropriate antithrombotic therapy, while the other patient had a contraindication to systemic anticoagulation. The procedure was successful using the modified implantation technique in all patients. The implanted device was the AMPLATZER™ Cardiac Plug (St. Jude Medical, Minneapolis, MN, USA) in one patient and the Amulet™ (St. Jude Medical, Minneapolis, MN, USA) in two patients. No periprocedural complications occurred. After a mean follow-up of 8±2 months, no deaths or late complications were observed.
Thrombus trapping is a feasible and effective technique for performing LAA occlusion in patients with thrombus within the LAA. This modification of the implantation technique may allow LAA closure indications to be extended to include patients with LAA thrombus, who were formerly considered unsuitable.
经皮左心耳(LAA)封堵术已成为预防非瓣膜性心房颤动高危患者栓塞性卒中的一种替代治疗选择。LAA内存在血栓目前是该手术的禁忌证。
描述一种改良的LAA封堵技术,使LAA有血栓的患者能够安全地进行手术。
2013年5月至2014年10月,对3例LAA有血栓的患者(平均年龄73.6±14岁;2例男性)进行LAA封堵,采用改良技术,避免在LAA内操作导管或进行血管造影。
2例患者尽管接受了适当的抗血栓治疗仍有持续性血栓,而另1例患者有全身抗凝的禁忌证。所有患者采用改良植入技术手术均成功。1例患者植入的装置为AMPLATZER™心脏封堵器(美国明尼阿波利斯市圣犹达医疗公司),2例患者植入的是Amulet™(美国明尼阿波利斯市圣犹达医疗公司)。围手术期未发生并发症。平均随访8±2个月后,未观察到死亡或晚期并发症。
血栓捕获是对LAA内有血栓的患者进行LAA封堵的一种可行且有效的技术。这种植入技术的改良可能会使LAA封堵的适应证扩大到包括以前被认为不适合的LAA有血栓的患者。